IN2013MN00329A - - Google Patents

Download PDF

Info

Publication number
IN2013MN00329A
IN2013MN00329A IN329MUN2013A IN2013MN00329A IN 2013MN00329 A IN2013MN00329 A IN 2013MN00329A IN 329MUN2013 A IN329MUN2013 A IN 329MUN2013A IN 2013MN00329 A IN2013MN00329 A IN 2013MN00329A
Authority
IN
India
Prior art keywords
formulation
present
relates
drug
pneumonias
Prior art date
Application number
Inventor
Geetanjali Chandrashekhar Chimote
Girish Badrinath Mahajan
Aravindan Vasudevan
Sivaramakrishnan Hariharan
Original Assignee
Piramal Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Entpr Ltd filed Critical Piramal Entpr Ltd
Publication of IN2013MN00329A publication Critical patent/IN2013MN00329A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Abstract

The present invention relates to a biodegradable inhalable microparticle formulation comprising a compound of formula I obtained by fermentation of a microorganism of the Streptomyces species ( PM 0626271 /MTCC5447) as described in PCT application publication WO201 1027290 and a biodegradable lipid for drug delivery wherein the ratio of drug (compound of formula I) to lipid is 1 :15 to 1 :25. The present invention also relates to the process for preparation of the formulation and to the method of treatment of pulmonary tuberculosis multi drug resistant tuberculosis (MDRTB) methicillin resistant Staphylococcus aureus (MRSA) pneumonias and methicillin sensitive Staphylococcus aureus (MSSA) pneumonias by administering therapeutically effective amount of the formulation to a mammal in need thereof. The present invention further relates to a method of delivering the microparticle formulation to a mammal in need thereof wherein the formulation is administered by inhalation or intratracheal instillation for pulmonary delivery.
IN329MUN2013 2010-08-05 2011-08-04 IN2013MN00329A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37091610P 2010-08-05 2010-08-05
PCT/IB2011/053470 WO2012017405A1 (en) 2010-08-05 2011-08-04 Microparticle formulation for pulmonary drug delivery of anti-infective molecule for treatment of infectious diseases

Publications (1)

Publication Number Publication Date
IN2013MN00329A true IN2013MN00329A (en) 2015-05-29

Family

ID=44653372

Family Applications (1)

Application Number Title Priority Date Filing Date
IN329MUN2013 IN2013MN00329A (en) 2010-08-05 2011-08-04

Country Status (14)

Country Link
US (1) US8697653B2 (en)
EP (1) EP2600842A1 (en)
JP (1) JP2013532722A (en)
KR (1) KR20130109106A (en)
CN (1) CN103442694B (en)
AU (1) AU2011287205A1 (en)
BR (1) BR112013002641A2 (en)
CA (1) CA2807357A1 (en)
IN (1) IN2013MN00329A (en)
MX (1) MX2013001325A (en)
RU (1) RU2013109384A (en)
TW (1) TW201208716A (en)
WO (1) WO2012017405A1 (en)
ZA (1) ZA201301662B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015107482A1 (en) * 2014-01-17 2015-07-23 Piramal Enterprises Limited Pharmaceutical combination for treatment of tuberculosis
US10335374B2 (en) 2014-12-04 2019-07-02 University System of Georgia, Valdosta State University Tablet composition for anti-tuberculosis antibiotics
CN109827875A (en) * 2019-04-10 2019-05-31 上海市食品药品检验所 A kind of device and method for measuring sucking preparation dissolution rate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8601457D0 (en) * 1986-04-01 1986-04-01 Draco Ab COMPOSITIONS OF LIPOSOMES AND B? 712 RECEPTOR ACTIVE SUBSTANCES FOR INHALATION
JPH0751496B2 (en) 1986-04-02 1995-06-05 武田薬品工業株式会社 Manufacturing method of liposome
TW497974B (en) * 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
EP1128813B1 (en) * 1998-11-12 2007-02-14 Inc. Transave An inhalation system
US20040254100A1 (en) * 2000-01-31 2004-12-16 Vermeulen Mary W. Use of thiostrepton as an anti-mycobacterial agent
AU2003225689B2 (en) * 2002-03-05 2009-03-26 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
WO2008127746A1 (en) * 2007-01-10 2008-10-23 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
US10501492B2 (en) 2009-09-02 2019-12-10 National Centre For Polar And Ocean Research (Ncpor) Antibiotic compounds

Also Published As

Publication number Publication date
CN103442694B (en) 2015-09-09
CN103442694A (en) 2013-12-11
TW201208716A (en) 2012-03-01
US20130125879A1 (en) 2013-05-23
AU2011287205A1 (en) 2013-03-07
RU2013109384A (en) 2014-09-10
CA2807357A1 (en) 2012-02-09
WO2012017405A1 (en) 2012-02-09
KR20130109106A (en) 2013-10-07
ZA201301662B (en) 2014-08-27
EP2600842A1 (en) 2013-06-12
JP2013532722A (en) 2013-08-19
MX2013001325A (en) 2013-10-28
BR112013002641A2 (en) 2016-06-07
US8697653B2 (en) 2014-04-15

Similar Documents

Publication Publication Date Title
Bassetti et al. Inhaled liposomal antimicrobial delivery in lung infections
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
PH12015500301A1 (en) A novel formulation of diclofenac
MX2012012225A (en) Nitric oxide releasing prodrugs of therapeutic agents.
MX2013013503A (en) Dry powder vancomycin compositions and associated methods.
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20230124862A1 (en) Bismuth thiol compounds and compositions and methods of treating microbial co-infections
PH12016500746A1 (en) A novel formulation of meloxicam
WO2011127302A3 (en) Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
NZ702799A (en) Methods and compositions for cns delivery of arylsulfatase a
IN2013MN00329A (en)
PH12014502802B1 (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
BRPI0719920B8 (en) quinoline derivative, its pharmaceutical composition, its use, its preparation process, combination and product comprising the same and intermediate compound
HK1137431A1 (en) Antibacterial quinoline derivatives
MX2014013056A (en) Antibacterial quinoline derivatives.
RU2013157933A (en) COMPOSITIONS, INCLUDING ANTIBACTERIAL MEANS AND PERSPECTIVES
CN112107676B (en) Lipopeptide and application thereof in antibiosis
EP3662924A1 (en) Compositions for treating lung infections by airway administration
IN2014MN02363A (en)
Espinoza-Gonzalez et al. Evaluation of the combined therapy of DA-7218, a new oxazolidinone, and trimethoprim/sulfamethoxazole in the treatment of experimental actinomycetoma by Nocardia brasiliensis
MX2014013055A (en) Antibacterial quinoline derivatives.
MX2012010528A (en) Pharmaceutical composition having antimicrobial and anti-inflammatory activity for parenteral administration, process for preparing same.
AU2014208310B2 (en) A Novel Formulation of Diclofenac
IN2013MU01154A (en)
RU2009145055A (en) MEDICINAL PRODUCT AND METHOD FOR IMPROVING THE RHEOLOGICAL PROPERTIES OF SPRAY AND INHALATION APPLICATION OF SUCH PRODUCT